The human microbiome represents the collection of trillions of microbes living in and on the human body. This may sound disturbing, but not all microbes make us sick. In fact, the vast majority of microbes play a role in many fundamental life processes, such as our digestion, development and protection from pathogens.
Over the past years, a large number of scientific breakthroughs have occurred with respect to understanding the importance of these bacteria in human health. In the longer term, these insights are likely to translate into new kinds of treatments based on bacteria.
A joint venture bringing life-changing treatments to patients
In 2019, Chr. Hansen took a quantum leap for its human microbiome lighthouse under Health & Nutrition when announcing a 50/50 joint venture with Swiss pharma contract manufacturer, Lonza AG. Now named Bacthera, which is a combination of the words; bacteriology, therapeutics and era, the new company has set out to enable customers to bring life-changing treatments to patients by pioneering the live biotherapeutic industry. Bacthera is a Contract Development & Manufacturing Organization that supports customers with Chemistry, Manufacturing & Control development and commercial supply of Live Biotherapeutic Products.